Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-08-03 09:33:16 | 0 | |||||
|
Functional Dyspepsia Treatment Trial Resource Report Resource Website |
Functional Dyspepsia Treatment Trial (RRID:SCR_006691) | FDTT | resource, clinical trial | Multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities. | antidepressant, amitriptyline, selective serotonin reuptake inhibitor, escitalopram, placebo |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Functional dyspepsia | NIDDK | PMID:22343090 | nlx_152830 | SCR_006691 | Antidepressant Therapy for Functional Dyspepsia, Functional Dyspepsia Treatment Trial (FDTT) | 2026-08-03 09:33:07 | 0 | |||||
|
Maryland Genetics of Interstitial Cystitis Resource Report Resource Website |
Maryland Genetics of Interstitial Cystitis (RRID:SCR_006992) | MaGIC | resource, clinical trial | Clinical study that investigated several hundred families with two or more blood relatives with interstitial cystitis in order to understand the molecular genetic basis of this condition. The study sought to find changes in genes that are found far more commonly in family members who have interstitial cystitis than in those who do not have the disease. Identifying these genes should lead to a better understanding of the cause of interstitial cystitis. This is a national study which is conducted by telephone and mail, and in which participants could participate entirely from their home. | male, female, adolescent, adult human, genetics, risk factor, family history, bladder, pain, observational |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Maryland School of Medicine; Maryland; USA |
Interstitial cystitis | NIDDK | nlx_152843 | http://icresearch.umaryland.edu/magic.aspx | SCR_006992 | Maryland Genetics of Interstitial Cystitis (MaGIC) | 2026-08-03 09:33:13 | 0 | |||||
|
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis Resource Report Resource Website |
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) | HUSC | resource, clinical trial | Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway. | treatment, placebo, ursodeoxycholic acid, intervention, randomized, adult human, male, female |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Primary Sclerosing Cholangitis | NIDDK | PMID:19585548 | nlx_152836 | SCR_006772 | Trial of High-dose Urso in Primary Sclerosing Cholangitis, High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (HUSC), Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis | 2026-08-03 09:33:14 | 0 | |||||
|
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit Resource Report Resource Website |
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) | GLND | resource, clinical trial | Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity. | parenteral nutrition, glutamine, glutamine dipeptide, clinical, outcome, adult human, mortality, nosocomial infection, immune cell function, hospital morbidity, morbidity, intensive care |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Emory University; Georgia; USA |
Critical illness | NIDDK U01DK069322 | PMID:18596310 | nlx_152823 | http://www.sph.emory.edu/GLND | SCR_006806 | Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients, Efficacy and Mechanisms of GLN Dipeptide in the SICU, Efficacy and Mechanisms of GLN Dipeptide in the SICU (GLND), GLND trial | 2026-08-03 09:33:15 | 0 | ||||
|
Diabetes Control and Complications Trial Resource Report Resource Website |
Diabetes Control and Complications Trial (RRID:SCR_006805) | DCCT | resource, clinical trial, data or information resource, database | Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk | blood glucose, adolescent, young human, middle adult human, longitudinal, eye disease, kidney disease, nerve disease, cardiovascular disease, heart attack, stroke, blood pressure, blood lipid, complication |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository is related to: Epidemiology of Diabetes Interventions and Complications is related to: Epidemiology of Diabetes Interventions and Complications is related to: NIDDK Information Network (dkNET) has parent organization: National Diabetes Information Clearinghouse |
Type 1 diabetes, Diabetes | NIDDK | nlx_152798 | SCR_006805 | DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study | 2026-08-03 09:33:10 | 0 | ||||||
|
Frequent Hemodialysis Network Nocturnal Trial Resource Report Resource Website |
Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) | FHN Nocturnal Trial | resource, clinical trial | Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia | hemodialysis, home, adult human, kidney, kidney disease |
is listed by: ClinicalTrials.gov is related to: Frequent Hemodialysis Network Daily Trial is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
End Stage Renal Disease, Hemodialysis | NIDDK | PMID:21775973 PMID:17164834 PMID:17699439 |
nlx_152829 | SCR_007014 | Frequent Hemodialysis Network (FHN) Nocturnal Trial, Frequent Hemodialysis Network: Nocturnal Trial | 2026-08-03 09:33:16 | 0 | |||||
|
Boston Area Diabetes Endocrinology Research Center Metabolic Physiology and Energy Balance Core Facility Resource Report Resource Website |
Boston Area Diabetes Endocrinology Research Center Metabolic Physiology and Energy Balance Core Facility (RRID:SCR_008293) | service resource, access service resource, core facility | Core in BADERC that provides services in consultation and teaching, use of DEXA scanner for determination of body fat and/or bone density, and use of Coulter Counter to measure cell number and cell size distribution. | animal physiology, metabolic physiology |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Harvard University; Cambridge; United States is organization facet of: Boston Area Diabetes Endocrinology Research Center |
Diabetes | NIDDK P30 DK057521 | Available to the research community, Fee for service | nlx_156297 | http://www.baderc.org/cores/metabolicCore.html | http://www.baderc.org/cores/metabolicCore.html | SCR_008293 | Boston Area Diabetes Endocrinology Research Center Metabolic Physiology | 2026-08-03 09:34:02 | 0 | ||||
|
Program to Reduce Incontinence by Diet and Exercise Resource Report Resource Website 5000+ mentions |
Program to Reduce Incontinence by Diet and Exercise (RRID:SCR_009018) | PRIDE | resource, clinical trial | Randomized controlled trial being conducted at two clinical centers in the United States to learn more about the effects of weight loss on urinary incontinence. About 330 overweight women aged 30 or older will participate and will be followed for 18 months. Efficacy of weight reduction as a treatment for urinary incontinence will be examined at 6 months following the intensive weight control program, and the sustained impact of the intervention will be examined at 18 months. To increase the maintenance of weight reduction and facilitate evaluation of the enduring impact of weight loss on urinary incontinence, they propose to study a motivation-based weight maintenance program. At the end of the intensive weight control program, women randomized to the weight loss program will be randomized to either a 12-month skill-based maintenance intervention or to a motivation-based maintenance intervention. The maintenance interventions maximize the potential for sustained weight loss and will allow them to determine if long-term weight reduction will produce continued improvement in urinary incontinence. | female, adult human, weight reduction, intervention, behavior, diet, exercise, motivation, weight maintenance |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: University of California at San Francisco; California; USA |
Urinary incontinence, Obesity, Weight loss, Overweight, Aging | NIDDK UO1 DK67860 | PMID:20664387 PMID:20680012 PMID:19179316 PMID:20643425 |
nlx_152847 | SCR_009018 | PRIDE (Program to Reduce Incontinence by Diet and Exercise) | 2026-08-03 09:34:18 | 6544 | |||||
|
ACCORD Resource Report Resource Website 100+ mentions |
ACCORD (RRID:SCR_009015) | ACCORD | resource, clinical trial | Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study. | middle adult human, late adult human, glycemic control, lowering lipid drug, blood pressure, lipid, clinical |
is related to: NIDDK Information Network (dkNET) has parent organization: National Heart Lung and Blood Institute |
Cardiovascular disease, Stroke, Type 2 diabetes, Diabetes, Aging | NHLBI ; NIDDK ; NEI ; CDC ; NIA |
PMID:23490598 PMID:23253271 PMID:23238658 PMID:22723583 PMID:22646230 |
nlx_152746 | SCR_009015 | Action to Control Cardiovascular Disease Risk in Diabetes | 2026-08-03 09:34:02 | 173 | |||||
|
Joslin Diabetes Center Flow Cytometry Core Facility Resource Report Resource Website 500+ mentions |
Joslin Diabetes Center Flow Cytometry Core Facility (RRID:SCR_009878) | service resource, access service resource, core facility | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides cell sorting and flow cytometry services. Specific services include cell analysis, large object sorting,magnetic cell enrichment, and automatic cell counting. | flow cytometry, flow cytometry service, cell sorting, cell analysis |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center is organization facet of: Joslin Diabetes Center |
Diabetes | NIDDK P30DK036836 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156348 | SCR_009878 | 2026-08-03 09:34:37 | 590 | |||||||
|
Joslin Diabetes Center Animal Physiology Core Facility Resource Report Resource Website 500+ mentions |
Joslin Diabetes Center Animal Physiology Core Facility (RRID:SCR_009876) | resource, service resource, access service resource, core facility | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides technically advanced physiological evaluation of metabolism in diabetes, obesity, and their associated complications in rodents for DRC investigators and outside users. It also provides training of investigators and trainees in several physiological procedures. | physiological evaluation, diabetes metabolism, obesity metabolism, rodent research, diabetes rodent research, physiological procedure training |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center is organization facet of: Joslin Diabetes Center |
Diabetes | NIDDK P30DK036836 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156346 | SCR_009876 | 2026-08-03 09:34:17 | 590 | |||||||
|
Joslin Diabetes Center Advanced Microscopy Core Facility Resource Report Resource Website 500+ mentions |
Joslin Diabetes Center Advanced Microscopy Core Facility (RRID:SCR_009875) | service resource, access service resource, core facility | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for performing specific morphological procedures, providing training and access to equipment, maintaining the specialized microscopes, and giving advice and interpretation. | morphology service, training service, microscope maintanence, |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center is organization facet of: Joslin Diabetes Center |
Diabetes | NIDDK P30DK036836 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156345 | SCR_009875 | 2026-08-03 09:34:37 | 590 | |||||||
|
Joslin Diabetes Center Advanced Genomics and Genetics Core Facility Resource Report Resource Website 500+ mentions |
Joslin Diabetes Center Advanced Genomics and Genetics Core Facility (RRID:SCR_009873) | service resource, access service resource, core facility | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for genetic and genomic analysis, including DNA extraction from blood, access to DNA collections from the Core?s repository, SNP genotyping, and support for gene expression studies based on both high-density oligonucleotide arrays and real-time quantitative PCR. | gene analysis, genome analysis, dna extraction, gene expression service |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center is organization facet of: Joslin Diabetes Center |
Diabetes | NIDDK P30DK036836 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156350 | SCR_009873 | 2026-08-03 09:34:17 | 590 | |||||||
|
Harvard Digestive Diseases Center Biomedical CORE B: Microscopy and Histopathology Resource Report Resource Website |
Harvard Digestive Diseases Center Biomedical CORE B: Microscopy and Histopathology (RRID:SCR_009836) | service resource, access service resource, core facility | Core facility that provides service for paraffin embedding, sectioning, staining, and frozen sectioning; shared equipment and service for confocal, widefield, photodocumentation, electron microscopy, and digital image processing; and an immunostaining service. | parrafin embedding, electron microscopy, immunostaining, digestive disease |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Harvard University; Cambridge; United States has parent organization: Harvard Digestive Disease Center is organization facet of: Harvard Digestive Disease Center |
digestive disease | NIDDK P30 DK034854 | Available to the research community | nlx_156305 | http://www.hms.harvard.edu/hddc/services/imaging/ChildrensHospitalBostonCoreB.htm | SCR_009836 | 2026-08-03 09:34:35 | 0 | ||||||
|
Harvard Digestive Diseases Center Biomedical CORE D: Gnotobiotic Mice, Microbiology and Metagenomics Resource Report Resource Website |
Harvard Digestive Diseases Center Biomedical CORE D: Gnotobiotic Mice, Microbiology and Metagenomics (RRID:SCR_012319) | Harvard Gnotobiotic and Microbiology Core | service resource, access service resource, core facility | Core facility that assists investigators evaluating host microbiota and its role in normal physiology and disease. It includes a number of resources for groups studying the role of the microbiota in human health and disease. | host microbiota, physiology, human health |
is listed by: ScienceExchange is listed by: NIDDK Information Network (dkNET) is related to: Harvard University Labs and Facilities has parent organization: Harvard University; Cambridge; United States has parent organization: Harvard Digestive Disease Center is organization facet of: Harvard Digestive Disease Center |
digestive disease | NIDDK P30 DK034854 | Available to the research community, Available to Harvard Medical School | SciEx_11652 | SCR_012319 | Harvard University Gnotobiotic and Microbiology Core, Harvard University Gnotobiotic and Microbiology Core (CHB), Harvard Gnotobiotic and Microbiology Core (CHB), Harvard Digestive Disease Center Gnotobiotics and Microbiology Core | 2026-08-03 09:34:51 | 0 | |||||
|
University of North Carolina at Chapel Hill Nutrition and Obesity Research Center Diet and Physical Activity Core Resource Report Resource Website |
University of North Carolina at Chapel Hill Nutrition and Obesity Research Center Diet and Physical Activity Core (RRID:SCR_012588) | UNC NORC - Diet Physical Activity and Body Composition Core | resource, service resource, access service resource, core facility | Core that provides diet, physical activity, or statistical analysis consultation, as well as consultation for the design and development of diet and physical activity data collection protocols. | diet analysis, physical activity analysis, statistical analysis consultation, experimental design consultation, data collection consultation |
is listed by: ScienceExchange is listed by: NIDDK Information Network (dkNET) is related to: University of North Carolina at Chapel Hill Labs and Facilities has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA has parent organization: University of North Carolina at Chapel Hill Nutrition and Obesity Research Center is organization facet of: University of North Carolina at Chapel Hill Nutrition and Obesity Research Center |
Obesity | NIDDK DK056350 | Available to the research community | SciEx_5107 | SCR_012588 | University of North Carolina at Chapel Hill NORC - Diet Physical Activity and Body Composition Core, UNC Nutrition Obesity Research Center - Diet Physical Activity and Body Composition Core, UNC-Chapel Hill NORC - Diet Physical Activity and Body Composition Core, University of North Carolina at Chapel Hill Nutrition Obesity Research Center - Diet Physical Activity and Body Composition Core | 2026-08-03 09:34:58 | 0 | |||||
|
Hyperglycemia and Pregnancy Outcomes Follow-Up Study Consortium (HAPO-FUS) Resource Report Resource Website |
Hyperglycemia and Pregnancy Outcomes Follow-Up Study Consortium (HAPO-FUS) (RRID:SCR_014377) | HAPO-FUS | data or information resource, data set | The goal of this follow-up study of mothers who participated in the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study is to determine the levels of blood sugar during pregnancy that are linked to increased body fat in the child, as well as to determine the chances of a mother developing diabetes 8-12 years after the pregnancy. The original study examined 23,316 mother-child pairs, and researchers determined that the hyperglycemia of a mother was linked to newborn birth weight and body fat. HAPO-FUS will enroll 7,000 or the original HAPO mother-child pairs for one follow-up visit to assess body composition, blucose metabolism, medical history, and other metabolic parameters. | follow up study, mother, body weight, newborn, child, pregnancy, hyperglycemia, blood sugar |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Hyperglycemia, Diabetes | http://www.niddk.nih.gov/research-funding/research-resources/Pages/default.aspx | SCR_014377 | Hyperglycemia and Pregnancy Outcomes Follow-Up Study Consortium | 2026-08-03 09:35:28 | 0 | |||||||
|
Nephrotic Syndrome Study Network (NEPTUNE) Resource Report Resource Website |
Nephrotic Syndrome Study Network (NEPTUNE) (RRID:SCR_014380) | NEPTUNE | data or information resource, data set | A consortium of researchers conducting a cohort study that investigates the underlying disease mechanisms of pro non-inflammatory glomerular diseases. The aim is to elucidate pathogenesis and identify therapeutic targets for clinical trials. The study participants will be classified according to the kidney biopsy results into one of three subcohorts, including Minimal change disease/Focal segmental glomerulosclerosis; Membranous nephropathy; and other conditions. | cohort study, pro non inflammatory glomerular disease, consortium, disease mechanism, pathogenesis, clinical trial, kidney |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Kidney diseases, Nephrotic syndrome, Renal insufficiency, Chronic, Minimal change disease/Focal segmental glomerulosclerosis, Membranous nephropathy | Study is ongoing, Publications are available | http://www.niddk.nih.gov/research-funding/research-resources/Pages/default.aspx | SCR_014380 | Nephrotic Syndrome Study Network | 2026-08-03 09:35:37 | 0 | ||||||
|
Einstein-Mount Sinai Diabetes Research Center Translational Research Core Facility Resource Report Resource Website |
Einstein-Mount Sinai Diabetes Research Center Translational Research Core Facility (RRID:SCR_015068) | service resource, access service resource, core facility | Core services include consultation, technical support and training and mentoring in clinical and translational research methods that are specifically applicable to diabetes, its complications and related metabolic disorders. Personel provides expertise in first-in-human and mechanistic studies in integrative physiology, in clinical trials of diabetes and obesity, and in application of new technologies. | translational research, data interpretation, diabetes research |
is listed by: NIDDK Information Network (dkNET) is listed by: ABRF CoreMarketplace has parent organization: Einstein-Mount Sinai Diabetes Research Center is organization facet of: Einstein-Mount Sinai Diabetes Research Center |
Diabetes | New York Obesity Research Center ; Center for the Study of Diabetic Complications ; Montefiore Clinical Diabetes Center ; NIDDK P30DK020541 |
Open | ABRF_2861 | https://coremarketplace.org/?FacilityID=2861&citation=1 | http://www.einstein.yu.edu/centers/diabetes-research/research-areas/biomedical-cores/translational-research-core/ | SCR_015068 | Einstein-Mount Sinai Diabetes Research Center Translational Research Core | 2026-08-03 09:35:44 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
